Menu
Search
|

Menu

Close
X

Opiant Pharmaceuticals Inc OPNT.OQ (NASDAQ Stock Exchange Capital Market)

16.24 USD
-- (--)
As of Jul 13
chart
Previous Close 16.24
Open --
Volume --
3m Avg Volume 8,384
Today’s High --
Today’s Low --
52 Week High 51.90
52 Week Low 12.75
Shares Outstanding (mil) 2.70
Market Capitalization (mil) 43.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
26
FY16
10
FY15
2
EPS (USD)
FY18
-3.676
FY17
2.446
FY16
-4.875
FY15
-3.870
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
2.53
8.07
Price to Book (MRQ)
vs sector
7.05
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
0.00
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-112.46
13.23
Return on Equity (TTM)
vs sector
-162.56
15.28

EXECUTIVE LEADERSHIP

Michael Sinclair
Executive Chairman of the Board, Since 2012
Salary: $314,583.00
Bonus: $10,000.00
Roger Crystal
President, Chief Executive Officer, Director, Since 2009
Salary: $402,083.00
Bonus: $50,000.00
David O'Toole
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Arvind Agrawal
Executive Vice President - Medical Affairs, Since 2015
Salary: --
Bonus: --
Phil Skolnick
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

201 Santa Monica Blvd Ste 500
SANTA MONICA   CA   90401-2213

Phone: +1310.5985410

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

SPONSORED STORIES